GenEditBio Secures FDA Clearance for GEB-101 Trial in Corneal Dystrophy

GenEditBio Limited has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application, enabling the company to begin Phase 1/2 trial activities for its lead in vivo genome-editing program, GEB-101. This trial targets TGFBI corneal dystrophy, a genetic eye disorder, and is set to evaluate the safety, tolerability, and efficacy of GEB-101 in affected patients.

The Phase 1/2 CLARITY trial is designed with a seamless, adaptive, multicenter approach. Participants will receive a single intrastromal injection of GEB-101, with enrollment anticipated to start in the second quarter of 2026 following site activation in the United States.

“This regulatory IND clearance for our lead clinical asset, GEB-101, marks a momentous milestone in our commitment towards bringing transformative ribonucleoprotein (RNP)-based therapies to patients globally,” stated Zongli Zheng, PhD, Chairman and Co-Founder of GenEditBio. Zheng emphasized that this achievement reflects the collective efforts of the company to advance its preclinical assets into clinical stages with professionalism and speed.

Tian Zhu, PhD, CEO and Co-Founder of GenEditBio, added that GEB-101 represents a first-in-class investigational therapy for TGFBI corneal dystrophy. Current treatment options are limited and do not address the underlying genetic causes of the disorder, underscoring a significant unmet medical need. “This IND clearance validates our robust preclinical data on safety and efficacy,” Zhu noted, expressing optimism about expanding the CLARITY trial into other major markets.

Understanding TGFBI Corneal Dystrophy

TGFBI corneal dystrophy encompasses a group of genetic disorders caused by mutations in the TGFBI gene. These mutations lead to abnormal protein accumulation in the cornea, which can result in symptoms such as photophobia, gradual vision loss, and recurrent corneal erosions that cause significant pain. Current treatments include phototherapeutic keratectomy (PTK) and corneal transplantation; however, these procedures have limitations, including high recurrence rates and potential complications that can threaten vision. This highlights the urgent need for innovative therapies.

About GEB-101 and GenEditBio

GEB-101 is a cutting-edge genome-editing candidate developed as a one-time treatment for TGFBI corneal dystrophy. Utilizing CRISPR-Cas genome-editing technology, GEB-101 targets a specific locus within the mutated TGFBI gene. The therapy is delivered in the form of ribonucleoprotein using an engineered protein delivery vehicle (PDV), a proprietary system developed by GenEditBio.

Founded in 2021 and headquartered in Hong Kong, GenEditBio aims to provide safe, precise, and affordable in vivo genome-editing solutions for genetic diseases. The company focuses on novel Cas nuclease discovery and efficient cargo delivery methods, maintaining research laboratories and offices in Hong Kong, Beijing, and Boston. GenEditBio is supported by prominent life science investors, including Qiming Venture Partners and Fangyuan Capital.

For further information about GenEditBio and its initiatives, please visit www.geneditbio.com.